Want to see AU:OCC full AI Analyst Report?
OCC Stock Chart & Stats
AU$0.71
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.71
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.70 - AU$1.60
Previous CloseN/A
Volume80.90K
Average Volume (3M)820.75K
Market Cap
AU$198.80M
Enterprise ValueAU$162.25M
Total Cash (Recent Filing)AU$44.37M
Total Debt (Recent Filing)AU$835.79K
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding272,331,970
10 Day Avg. Volume747,972
30 Day Avg. Volume820,745
Financial Highlights & Ratios
PEG Ratio-3.76
Price to Book (P/B)18.08
Price to Sales (P/S)34.89
P/FCF Ratio-29.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.19Price Target Upside67.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)AU$21.30M
Bulls Say, Bears Say
Bulls Say
Commercialised Regenerative Product PortfolioOwning approved, sellable products (Remplir, Striate+/CelGro) provides recurring revenue channels and reduces binary R&D risk. Durable commercial offerings support surgeon adoption, distribution scaling and incremental margin improvement as volumes and procedural penetration rise over months.
Sustained Top-line GrowthConsistent revenue growth signals expanding market acceptance and supports investments in manufacturing, regulatory and commercial capability. Over a 2-6 month horizon, rising sales trends enhance scale economics and underpin longer-term commercialization and reimbursement efforts.
Low Leverage And Healthy Equity BaseVery low debt gives financial flexibility to fund operations, R&D and regulatory work without heavy interest burdens. A strong equity position reduces refinancing risk and preserves optionality for strategic partnerships or measured capital raises to support commercialization.
Bears Say
Persistent UnprofitabilityOngoing negative net and EBIT margins indicate the business is not yet self-sustaining. Persistent losses constrain reinvestment, raise dependency on external capital, and pressure long-term viability if margin improvement and pricing/reimbursement gains do not materialize within the planning horizon.
Negative Operating Cash FlowNegative operating cash flow undermines runway and forces reliance on financing or equity raises to fund growth and regulatory activity. Even with improved FCF growth, sustained negative OCF threatens operational resilience and could dilute shareholders if external funding is required.
Poor Returns On CapitalNegative ROE shows the company is not converting shareholder capital into profits, signaling inefficient capital deployment. Over months this raises concerns about long-term value creation and the ability to justify additional capital for scaling commercial operations.
Orthocell Ltd News
OCC FAQ
What was Orthocell Ltd’s price range in the past 12 months?
Orthocell Ltd lowest share price was AU$0.70 and its highest was AU$1.60 in the past 12 months.
What is Orthocell Ltd’s market cap?
Orthocell Ltd’s market cap is AU$198.80M.
When is Orthocell Ltd’s upcoming earnings report date?
Orthocell Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 22 days.
How were Orthocell Ltd’s earnings last quarter?
Orthocell Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.021.
Is Orthocell Ltd overvalued?
According to Wall Street analysts Orthocell Ltd’s price is currently Undervalued.
Does Orthocell Ltd pay dividends?
Orthocell Ltd does not currently pay dividends.
What is Orthocell Ltd’s EPS estimate?
Orthocell Ltd’s EPS estimate is 0.
How many shares outstanding does Orthocell Ltd have?
Orthocell Ltd has 272,331,970 shares outstanding.
What happened to Orthocell Ltd’s price movement after its last earnings report?
Orthocell Ltd reported an EPS of -AU$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Orthocell Ltd?
Currently, no hedge funds are holding shares in AU:OCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthocell Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.19 (67.61% Upside)
AU$1.19 (67.61% Upside)
Blogger Sentiment
Bullish
AU:OCC Sentiment 94%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
49.36%
Trailing 12-Months
Company Description
Orthocell Ltd
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.
OCC Stock 12 Month Forecast
Average Price Target
AU$1.19
▲(67.61% Upside)
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―






